FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE)
CUSIP: 31189P102
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 122,342,805
- Total 13F shares
- 72,134,393
- Share change
- -11,206
- Total reported value
- $70,931,182
- Put/Call ratio
- 436%
- Price per share
- $0.98
- Number of holders
- 144
- Value change
- -$426,358
- Number of buys
- 48
- Number of sells
- 69
Quarterly Holders Quick Answers
What is CUSIP 31189P102?
CUSIP 31189P102 identifies FATE - FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 31189P102:
Top shareholders of FATE - FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Redmile Group, LLC |
13F
|
Company |
11%
|
12,872,946
|
$16,219,912 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
6.9%
from 13D/G
|
10,680,727
|
$13,457,714 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
7.2%
|
8,798,491
|
$11,086,098 | — | 30 Sep 2025 | |
| Wilshire Advisors LLC |
13F
|
Company |
6.9%
|
8,486,822
|
$10,693,396 | — | 30 Sep 2025 | |
| JOHNSON & JOHNSON |
13F
|
Company |
2.8%
|
3,379,064
|
$4,257,621 | — | 30 Sep 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
2.2%
|
2,710,234
|
$3,412,000 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.1%
|
2,530,212
|
$3,188,561 | — | 30 Sep 2025 | |
| Vestal Point Capital, LP |
13F
|
Company |
2.1%
|
2,515,000
|
$3,168,900 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
2%
|
2,417,135
|
$3,045,590 | — | 30 Sep 2025 | |
| J. Scott Wolchko |
3/4/5
|
President and CEO, Director |
—
mixed-class rows
|
871,248
mixed-class rows
|
$2,987,354 | — | 01 Feb 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1.7%
|
2,094,975
|
$2,637,886 | — | 30 Sep 2025 | |
| GOLDMAN SACHS GROUP INC |
13D/G
13F
|
THE GOLDMAN SACHS GROUP, INC. · Company |
2%
|
2,274,020
|
$2,546,902 | -$6,958,784 | 30 Jun 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
1.5%
|
1,867,773
|
$2,353,394 | — | 30 Sep 2025 | |
| Edward J. Dulac III |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
526,479
mixed-class rows
|
$1,948,742 | — | 04 Mar 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
1%
|
1,262,515
|
$1,590,769 | — | 30 Sep 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.92%
|
1,131,414
|
$1,425,581 | — | 30 Sep 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.82%
|
1,007,400
|
$1,269,324 | — | 30 Sep 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.79%
|
963,871
|
$1,214,477 | — | 30 Sep 2025 | |
| Jerome Charles Bressi |
3/4/5
|
Chief Regulatory and Quality Officer |
—
mixed-class rows
|
585,203
mixed-class rows
|
$1,202,065 | — | 15 Jan 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.76%
|
929,944
|
$1,171,730 | — | 30 Sep 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.74%
|
900,757
|
$1,134,954 | — | 30 Sep 2025 | |
| Schonfeld Strategic Advisors LLC |
13D/G
13F
|
Company |
0.82%
|
937,521
|
$1,050,024 | -$7,679,831 | 30 Jun 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.67%
|
824,545
|
$1,038,927 | — | 30 Sep 2025 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.67%
|
814,639
|
$1,026,445 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.67%
|
814,465
|
$1,026,226 | — | 30 Sep 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.64%
|
785,921
|
$990,260 | — | 30 Sep 2025 | |
| Monaco Asset Management SAM |
13F
|
Company |
0.63%
|
770,000
|
$970,200 | — | 30 Sep 2025 | |
| Bruce & Co., Inc. |
13F
|
Company |
0.6%
|
729,188
|
$918,777 | — | 30 Sep 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.58%
|
712,650
|
$897,939 | — | 30 Sep 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.49%
|
603,761
|
$760,739 | — | 30 Sep 2025 | |
| Yu-Waye Chu |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
140,676
|
$614,754 | — | 18 Apr 2023 | |
| Graham Capital Management, L.P. |
13F
|
Company |
0.38%
|
469,071
|
$591,029 | — | 30 Sep 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.36%
|
437,918
|
$551,777 | — | 30 Sep 2025 | |
| Mark Plavsic |
3/4/5
|
Chief Technical Officer |
—
class O/S missing
|
123,705
|
$540,591 | — | 10 Jan 2023 | |
| Quadrature Capital Ltd |
13F
|
Company |
0.31%
|
377,357
|
$475,470 | — | 30 Sep 2025 | |
| David M. Knott Jr. |
13F
|
Individual |
0.3%
|
365,000
|
$459,900 | — | 30 Sep 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.28%
|
336,872
|
$424,458 | — | 30 Sep 2025 | |
| Privium Fund Management B.V. |
13F
|
Company |
0.27%
|
333,219
|
$419,856 | — | 30 Sep 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.26%
|
316,336
|
$398,583 | — | 30 Sep 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.26%
|
314,825
|
$396,680 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0.26%
|
314,759
|
$396,596 | — | 30 Sep 2025 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.25%
|
310,826
|
$392,000 | — | 30 Sep 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.21%
|
261,671
|
$329,705 | — | 30 Sep 2025 | |
| Man Group plc |
13F
|
Company |
0.18%
|
219,658
|
$276,769 | — | 30 Sep 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.17%
|
210,487
|
$265,213 | — | 30 Sep 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.15%
|
187,700
|
$236,502 | — | 30 Sep 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.15%
|
187,335
|
$236,000 | — | 30 Sep 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.15%
|
178,927
|
$225,448 | — | 30 Sep 2025 | |
| Neelufar Mozaffarian |
3/4/5
|
Director |
—
class O/S missing
|
55,000
|
$218,400 | — | 29 May 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.13%
|
157,159
|
$198,020 | — | 30 Sep 2025 |
Institutional Holders of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) as of Q4 2025
As of 31 Dec 2025,
FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) was held by
144 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
72,134,393 shares.
The largest 10 holders included
Redmile Group, LLC, BlackRock, Inc., VANGUARD GROUP INC, JOHNSON & JOHNSON, ACADIAN ASSET MANAGEMENT LLC, GEODE CAPITAL MANAGEMENT, LLC, RENAISSANCE TECHNOLOGIES LLC, STATE STREET CORP, TWO SIGMA INVESTMENTS, LP, and Vestal Point Capital, LP.
This page lists
144
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
138
Q4 2025 holders
144
Holder diff
6
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.